An interventional study of Experimental follow up and Genetic sample in Bipolar Disorder and Euthymic State, sponsored by Assistance Publique - Hôpitaux de Paris. Status unknown at 1 site in France. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2017-06-20.
Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Other
Study in 400 patients with bipolar disorder I or II, of relapse risk factors. The principal objective of this research is to test the predictive value of core vulnerability dimensions such as affective instability and emotional reactivity, measured by validated questionnaires (AIM and ALS) on recurrence of affective major episode (depressed, hypomanic or manic) during a 24 months prospective follow-up.
In addition, several arguments suggest that inter-individual variability in the risk of relapse is influenced by genetic factors. In particular, the implication of such factors have been demonstrated in rapid cycling or antidepressants induced mania. However, this has never been tested in cohorts followed prospectively. Finally, the existence of neuropsychological deficits in bipolar disorder is well documented and their role in the risk of relapse is suspected. Yet the nature of these deficits, their origin and evolutionary course remain poorly investigated. In summary, the secondary objectives of this research are the study of the influence of these other clinical, neuropsychological and genetic factors on the risk of relapse.
Other factors that may influence the risk of relapse have been suggested in the literature but have not been formally tested in prospective studies:
The role of certain inflammatory and infectious factors in the etiology of bipolar disorder has been suggested but it is clear whether these biomarkers are "state" or "traits". Thus, the role of neurotoxic inflammatory or infectious factors in relapse mood has never been tested in a prospective follow up studies.
Determine whether the neuropsychological deficits observed in euthymic bipolar patients that contribute to functional impairment worsen with time.
DNA collection to test the involvement of candidate genes Serum collection to study the biological and infectious biomarkers
4,279 studies on the registry are indexed under Recurrence; 988 are open to participants now.
This study's enrollment of 274 is above the median of 50 across 3,374 interventional studies indexed under Recurrence.
Browse Recurrence studies →Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,505 studies on the registry; 1,006 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Experimental follow up : Neuropsychological assessment at 6 month and genetic samples
Other: Experimental follow up · Genetic: Genetic sample
Neuropsychological assessment (intellectual functioning, episodic verbal memory, processing speed, attention, working verbal memory, working visual memory, executive function)
Blood samples
Combined outcome based on AIM and ALS's score assessed at baseline in euthymic bipolar patients associated with relapse in patients during a 2 years follow-up period.
Time frame: 24 months
Global neuropsychological performance based on combined score of all neuropsychological scales (detail below) at T0, measured in euthymic patients predict relapse during a 2 years follow-up period.
Neuropsychological scales : intellectual functioning, episodic verbal memory, processing speed, attention, working verbal memory, working visual memory, executive function
Time frame: 24 months
Global neuropsychological deficits based on combined score of all neuropsychological scales (detail below) observed in euthymic bipolar patients that contribute to functional impairment worsen with time
Neuropsychological scales : intellectual functioning, episodic verbal memory, processing speed, attention, working verbal memory, working visual memory, executive function
Time frame: 24 months
This study is status unknown, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris